Bio Medica Laboratories's Days Sales Outstanding for the
six
months ended in Mar. 2025 was 30.75.
Bio Medica Laboratories's Days Inventory for the
six
months ended in Mar. 2025 was 229.66.
Bio Medica Laboratories's Days Payable for the
six
months ended in Mar. 2025 was 56.75.
Therefore, Bio Medica Laboratories's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2025 was 203.66.
Bio Medica Laboratories (NSE:BMLL) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Bio Medica Laboratories Cash Conversion Cycle Related Terms
Bio Medica Laboratories Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Bio Medica Laboratories's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Cash Conversion Cycle Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Cash Conversion Cycle
72.18
188.71
203.66
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Cash Conversion Cycle
72.18
188.71
203.66
NSE:BMLL vs ISRG, BDX, MDLN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Cash Conversion Cycle falls into.
Bio Medica Laboratories Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Bio Medica Laboratories's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories (NSE:BMLL) has a Cash Conversion Cycle of 203.66 as of Mar. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bio Medica Laboratories and its competitors.
Is Bio Medica Laboratories' Cash Conversion Cycle too high?
Bio Medica Laboratories' current Cash Conversion Cycle is 203.66. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Bio Medica Laboratories' value of 203.66 is 30.2% above this industry median. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Cash Conversion Cycle compare to ISRG and BDX?
Bio Medica Laboratories' Cash Conversion Cycle of 203.66 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Bio Medica Laboratories' value of 203.66 is 30.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current Cash Conversion Cycle of 203.66 is 30.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current Cash Conversion Cycle is 203.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Cash Conversion Cycle of 203.66. The current Cash Conversion Cycle is 203.66 and 30.2% above the Medical Devices & Instruments industry median of 156.39. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Cash Conversion Cycle is 203.66 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 